ClinicalTrials.gg
CompletedNCT01486979Updated Feb 8, 2017

Pharmacokinetic Assessment of the Absorption of Estradiol in Postmenopausal Women With Atrophic Vaginitis

A Phase 1 interventional study of estradiol, 10 mcg and estradiol, 25 mcg in Menopause and Postmenopausal Vaginal Atrophy, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to female participants aged 60 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-02-08.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
60 Years to 70 Years
Sex
Female
01

Study summary

This trial is conducted in Europe. The aim of this trial is to to evaluate the extent of systemic absorption of estradiol during treatment with two different doses of estradiol in postmenopausal women with atrophic vaginitis.

02

Conditions studied

  • Menopause
  • Postmenopausal Vaginal Atrophy
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are able to use German language in speaking and writing
  • women with at least 5 years after last menstruation, or bilateral oophorectomy performed two years or more prior to the time of screening
  • Serum FSH (Follicle Stimulating Hormone) levels above 40 mIU/ml and estradiol below 20 pg/ml
  • Maximum 5% superficial cells as assessed by evaluation of vaginal cytology
  • Endometrial thickness below 4.0 mm (double layer), as measured by transvaginal ultrasound (if applicable)
  • Availability of a normal mammogram within one year prior to trial start
  • Good general health as assessed by the Investigator and based on medical history, and physical and laboratory examinations

Exclusion criteria

Exclusion Criteria:

  • Known or suspected allergy to trial product or related products
  • Known, suspected or past history of breast cancer
  • Known, suspected or past estrogen dependent neoplasia e.g. endometrial cancer
  • Endometrial hyperplasia or endometrial polyps diagnosed during the screening period
  • Abnormal genital bleeding of unknown etiology
  • Previous estrogen and/ or progestin hormone replacement therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Low dose

    Drug: estradiol, 10 mcg

  • Active comparator
    High dose

    Drug: estradiol, 25 mcg

Interventions

  • One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks

  • One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks

06

What researchers measure

Primary outcomes

  1. Area under the curve (AUC)

Secondary outcomes

  1. Average plasma concentration (C average)

  2. Maximal concentration (Cmax)

  3. Minimal concentration (Cmin)

  4. Time of maximal concentration (tmax)

  5. Incidence of adverse events

07

Study locations

1 site
  • Novo Nordisk Investigational Site
    Neu-Ulm, 89231, Germany
08

References and documents

Publications

  • Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. Climacteric. 2010 Jun;13(3):219-27. doi: 10.3109/13697137.2010.483297. PubMed 20423242 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of May 2007 and a completion of May 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2011
First posted
Dec 7, 2011
Start
Jan 2007
Primary completionActual
May 2007
CompletionActual
May 2007
Last update
Feb 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01486979
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 7, 2011
Start date
Jan 2007
Primary completion
May 2007
Completion
May 2007
Last update
Feb 8, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion